Vimta Labs Limited (VIMTALABS.NS)
INR 1016.0
(2.42%)
INR 1016.0
(2.42%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.18 Billion INR | 0.02% |
| 2022 | 3.18 Billion INR | 15.31% |
| 2021 | 2.75 Billion INR | 32.3% |
| 2020 | 2.08 Billion INR | 15.44% |
| 2019 | 1.8 Billion INR | -15.03% |
| 2018 | 2.12 Billion INR | 17.42% |
| 2017 | 1.81 Billion INR | 18.08% |
| 2016 | 1.53 Billion INR | 22.98% |
| 2015 | 1.24 Billion INR | 16.25% |
| 2014 | 1.07 Billion INR | -9.33% |
| 2013 | 1.18 Billion INR | 8.44% |
| 2012 | 1.09 Billion INR | 24.91% |
| 2011 | 873.44 Million INR | -8.73% |
| 2010 | 957.01 Million INR | 10.25% |
| 2009 | 868.02 Million INR | 6.37% |
| 2008 | 816.03 Million INR | 6.4% |
| 2007 | 766.93 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 817.55 Million INR | 2.59% |
| 2023 Q1 | 834.85 Million INR | 2.03% |
| 2023 Q2 | 734.09 Million INR | -12.07% |
| 2023 Q4 | 796.88 Million INR | -2.44% |
| 2023 Q3 | 816.79 Million INR | 11.27% |
| 2023 FY | 3.18 Billion INR | 0.02% |
| 2022 Q3 | 773.84 Million INR | -3.09% |
| 2022 Q4 | 818.2 Million INR | 5.73% |
| 2022 FY | 3.18 Billion INR | 15.31% |
| 2022 Q1 | 791.32 Million INR | 10.29% |
| 2022 Q2 | 798.54 Million INR | 0.91% |
| 2021 FY | 2.75 Billion INR | 32.3% |
| 2021 Q1 | 613.54 Million INR | 6.28% |
| 2021 Q2 | 754.97 Million INR | 23.05% |
| 2021 Q4 | 717.51 Million INR | 6.55% |
| 2021 Q3 | 673.4 Million INR | -10.8% |
| 2020 Q4 | 577.3 Million INR | -1.61% |
| 2020 Q2 | 593.82 Million INR | 81.15% |
| 2020 Q1 | 327.8 Million INR | -24.17% |
| 2020 FY | 2.08 Billion INR | 15.44% |
| 2020 Q3 | 586.76 Million INR | -1.19% |
| 2019 Q2 | 424.53 Million INR | -3.61% |
| 2019 Q4 | 432.27 Million INR | -16.04% |
| 2019 FY | 1.8 Billion INR | -15.03% |
| 2019 Q1 | 440.44 Million INR | -17.8% |
| 2019 Q3 | 514.83 Million INR | 21.27% |
| 2018 Q4 | 535.83 Million INR | 5.72% |
| 2018 FY | 2.12 Billion INR | 17.42% |
| 2018 Q3 | 506.86 Million INR | -5.83% |
| 2018 Q2 | 538.26 Million INR | -1.32% |
| 2018 Q1 | 545.46 Million INR | 5.02% |
| 2017 Q1 | 390.37 Million INR | -4.03% |
| 2017 Q4 | 519.39 Million INR | 9.43% |
| 2017 FY | 1.81 Billion INR | 18.08% |
| 2017 Q3 | 474.62 Million INR | 11.27% |
| 2017 Q2 | 426.55 Million INR | 9.27% |
| 2016 Q2 | 372.38 Million INR | -1.55% |
| 2016 Q1 | 378.25 Million INR | 14.93% |
| 2016 Q4 | 406.78 Million INR | 4.75% |
| 2016 FY | 1.53 Billion INR | 22.98% |
| 2016 Q3 | 388.33 Million INR | 4.28% |
| 2015 FY | 1.24 Billion INR | 16.25% |
| 2015 Q4 | 329.11 Million INR | 11.01% |
| 2015 Q2 | 339.69 Million INR | 20.54% |
| 2015 Q3 | 296.48 Million INR | -12.72% |
| 2015 Q1 | 281.79 Million INR | -0.84% |
| 2014 Q3 | 251.52 Million INR | 0.39% |
| 2014 Q4 | 284.17 Million INR | 12.98% |
| 2014 Q2 | 250.54 Million INR | -12.54% |
| 2014 FY | 1.07 Billion INR | -9.33% |
| 2014 Q1 | 286.47 Million INR | -2.34% |
| 2013 Q2 | 305.45 Million INR | 11.36% |
| 2013 Q4 | 293.35 Million INR | -5.39% |
| 2013 FY | 1.18 Billion INR | 8.44% |
| 2013 Q3 | 310.05 Million INR | 1.5% |
| 2013 Q1 | 274.29 Million INR | -3.86% |
| 2012 Q4 | 285.3 Million INR | 7.5% |
| 2012 FY | 1.09 Billion INR | 24.91% |
| 2012 Q1 | 263.85 Million INR | 17.75% |
| 2012 Q3 | 265.38 Million INR | -4.02% |
| 2012 Q2 | 276.49 Million INR | 4.79% |
| 2011 FY | 873.44 Million INR | -8.73% |
| 2011 Q4 | 224.07 Million INR | 11.19% |
| 2011 Q3 | 201.51 Million INR | -0.45% |
| 2011 Q2 | 202.42 Million INR | 0.0% |
| 2010 FY | 957.01 Million INR | 10.25% |
| 2009 FY | 868.02 Million INR | 6.37% |
| 2008 FY | 816.03 Million INR | 6.4% |
| 2007 FY | 766.93 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Krsnaa Diagnostics Limited | 6.19 Billion INR | 48.637% |
| Dr. Lal PathLabs Limited | 22.26 Billion INR | 85.707% |
| Metropolis Healthcare Limited | 12.07 Billion INR | 73.648% |
| Thyrocare Technologies Limited | 5.71 Billion INR | 44.348% |
| Vijaya Diagnostic Centre Limited | 5.47 Billion INR | 41.903% |